Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

The impact of postsynaptic density 95 blocking peptide (Tat-NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate-induced epileptogenesis.

Tse K, Hammond D, Simpson D, Beynon RJ, Beamer E, Tymianski M, Salter MW, Sills GJ, Thippeswamy T.

J Neurosci Res. 2019 May 15. doi: 10.1002/jnr.24441. [Epub ahead of print]

PMID:
31090233
2.

Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy.

Walker LE, Frigerio F, Ravizza T, Ricci E, Tse K, Jenkins RE, Sills GJ, Jorgensen A, Porcu L, Thippeswamy T, Alapirtti T, Peltola J, Brodie MJ, Park BK, Marson AG, Antoine DJ, Vezzani A, Pirmohamed M.

J Clin Invest. 2019 Apr 8;130:2166. doi: 10.1172/JCI129285. eCollection 2019 Apr 8. No abstract available.

3.

A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine.

Berghuis B, Stapleton C, Sonsma ACM, Hulst J, de Haan GJ, Lindhout D, Demurtas R; EpiPGX Consortium, Krause R, Depondt C, Kunz WS, Zara F, Striano P, Craig J, Auce P, Marson AG, Stefansson H, O'Brien TJ, Johnson MR, Sills GJ, Wolking S, Lerche H, Sisodiya SM, Sander JW, Cavalleri GL, Koeleman BPC, McCormack M.

Epilepsia Open. 2019 Jan 17;4(1):102-109. doi: 10.1002/epi4.12297. eCollection 2019 Mar.

4.

A Caenorhabditis elegans assay of seizure-like activity optimised for identifying antiepileptic drugs and their mechanisms of action.

Wong SQ, Jones A, Dodd S, Grimes D, Barclay JW, Marson AG, Cunliffe VT, Burgoyne RD, Sills GJ, Morgan A.

J Neurosci Methods. 2018 Nov 1;309:132-142. doi: 10.1016/j.jneumeth.2018.09.004. Epub 2018 Sep 3.

5.

Rare coding variants in genes encoding GABAA receptors in genetic generalised epilepsies: an exome-based case-control study.

May P, Girard S, Harrer M, Bobbili DR, Schubert J, Wolking S, Becker F, Lachance-Touchette P, Meloche C, Gravel M, Niturad CE, Knaus J, De Kovel C, Toliat M, Polvi A, Iacomino M, Guerrero-López R, Baulac S, Marini C, Thiele H, Altmüller J, Jabbari K, Ruppert AK, Jurkowski W, Lal D, Rusconi R, Cestèle S, Terragni B, Coombs ID, Reid CA, Striano P, Caglayan H, Siren A, Everett K, Møller RS, Hjalgrim H, Muhle H, Helbig I, Kunz WS, Weber YG, Weckhuysen S, Jonghe P, Sisodiya SM, Nabbout R, Franceschetti S, Coppola A, Vari MS, Kasteleijn-Nolst Trenité D, Baykan B, Ozbek U, Bebek N, Klein KM, Rosenow F, Nguyen DK, Dubeau F, Carmant L, Lortie A, Desbiens R, Clément JF, Cieuta-Walti C, Sills GJ, Auce P, Francis B, Johnson MR, Marson AG, Berghuis B, Sander JW, Avbersek A, McCormack M, Cavalleri GL, Delanty N, Depondt C, Krenn M, Zimprich F, Peter S, Nikanorova M, Kraaij R, van Rooij J, Balling R, Ikram MA, Uitterlinden AG, Avanzini G, Schorge S, Petrou S, Mantegazza M, Sander T, LeGuern E, Serratosa JM, Koeleman BPC, Palotie A, Lehesjoki AE, Nothnagel M, Nürnberg P, Maljevic S, Zara F, Cossette P, Krause R, Lerche H; Epicure Consortium; EuroEPINOMICS CoGIE Consortium; EpiPGX Consortium.

Lancet Neurol. 2018 Aug;17(8):699-708. doi: 10.1016/S1474-4422(18)30215-1. Epub 2018 Jul 17.

6.

Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients.

McCormack M, Gui H, Ingason A, Speed D, Wright GEB, Zhang EJ, Secolin R, Yasuda C, Kwok M, Wolking S, Becker F, Rau S, Avbersek A, Heggeli K, Leu C, Depondt C, Sills GJ, Marson AG, Auce P, Brodie MJ, Francis B, Johnson MR, Koeleman BPC, Striano P, Coppola A, Zara F, Kunz WS, Sander JW, Lerche H, Klein KM, Weckhuysen S, Krenn M, Gudmundsson LJ, Stefánsson K, Krause R, Shear N, Ross CJD, Delanty N; EPIGEN Consortium;, Pirmohamed M, Carleton BC; Canadian Pharmacogenomics Network for Drug Safety;, Cendes F, Lopes-Cendes I, Liao WP, O'Brien TJ, Sisodiya SM; EpiPGX Consortium;, Cherny S, Kwan P, Baum L; International League Against Epilepsy Consortium on Complex Epilepsies;, Cavalleri GL.

Neurology. 2018 Jan 23;90(4):e332-e341. doi: 10.1212/WNL.0000000000004853. Epub 2017 Dec 29. Erratum in: Neurology. 2018 Oct 16;91(16):765.

7.

Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis.

Androsova G, Krause R, Borghei M, Wassenaar M, Auce P, Avbersek A, Becker F, Berghuis B, Campbell E, Coppola A, Francis B, Wolking S, Cavalleri GL, Craig J, Delanty N, Koeleman BPC, Kunz WS, Lerche H, Marson AG, Sander JW, Sills GJ, Striano P, Zara F, Sisodiya SM, Depondt C; EpiPGX Consortium.

Epilepsia. 2017 Oct;58(10):1734-1741. doi: 10.1111/epi.13871. Epub 2017 Aug 31.

8.

Prospective clinical trials to investigate clinical and molecular biomarkers.

Auvin S, Walker L, Gallentine W, Jozwiak S, Tombini M, Sills GJ.

Epilepsia. 2017 Jul;58 Suppl 3:20-26. doi: 10.1111/epi.13782. Review.

9.

Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy.

Walker LE, Frigerio F, Ravizza T, Ricci E, Tse K, Jenkins RE, Sills GJ, Jorgensen A, Porcu L, Thippeswamy T, Alapirtti T, Peltola J, Brodie MJ, Park BK, Marson AG, Antoine DJ, Vezzani A, Pirmohamed M.

J Clin Invest. 2017 Jun 1;127(6):2118-2132. doi: 10.1172/JCI92001. Epub 2017 May 15. Retraction in: J Clin Invest. 2019 Apr 8;130:2166.

10.

Genetic regulation of gene expression in the epileptic human hippocampus.

Mirza N, Appleton R, Burn S, du Plessis D, Duncan R, Farah JO, Feenstra B, Hviid A, Josan V, Mohanraj R, Shukralla A, Sills GJ, Marson AG, Pirmohamed M.

Hum Mol Genet. 2017 May 1;26(9):1759-1769. doi: 10.1093/hmg/ddx061.

11.

Identifying new antiepileptic drugs through genomics-based drug repurposing.

Mirza N, Sills GJ, Pirmohamed M, Marson AG.

Hum Mol Genet. 2017 Feb 1;26(3):527-537. doi: 10.1093/hmg/ddw410.

PMID:
28053048
12.

A comparison of HMGB1 concentrations between cerebrospinal fluid and blood in patients with neurological disease.

Walker LE, Griffiths MJ, McGill F, Lewthwaite P, Sills GJ, Jorgensen A, Antoine DJ, Solomon T, Marson AG, Pirmohamed M.

Biomarkers. 2017 Nov;22(7):635-642. doi: 10.1080/1354750X.2016.1265003. Epub 2016 Dec 8.

PMID:
27899037
13.

Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation.

Wadsworth I, Jaki T, Sills GJ, Appleton R, Cross JH, Marson AG, Martland T, McLellan A, Smith PE, Pellock JM, Hampson LV.

CNS Drugs. 2016 Nov;30(11):1011-1017. Review.

14.

An integrative in silico system for predicting dysregulated genes in the human epileptic focus: Application to SLC transporters.

Mirza N, Vasieva O, Appleton R, Burn S, Carr D, Crooks D, du Plessis D, Duncan R, Farah JO, Josan V, Miyajima F, Mohanraj R, Shukralla A, Sills GJ, Marson AG, Pirmohamed M.

Epilepsia. 2016 Sep;57(9):1467-74. doi: 10.1111/epi.13473. Epub 2016 Jul 16.

15.

NRSF and BDNF polymorphisms as biomarkers of cognitive dysfunction in adults with newly diagnosed epilepsy.

Warburton A, Miyajima F, Shazadi K, Crossley J, Johnson MR, Marson AG, Baker GA, Quinn JP, Sills GJ.

Epilepsy Behav. 2016 Jan;54:117-27. doi: 10.1016/j.yebeh.2015.11.013. Epub 2015 Dec 17.

16.

Sulthiame add-on therapy for epilepsy.

Milburn-McNulty P, Powell G, Sills GJ, Marson AG.

Cochrane Database Syst Rev. 2015 Oct 28;(10):CD009472. doi: 10.1002/14651858.CD009472.pub3. Review.

PMID:
26510094
17.

Identifying the biological pathways underlying human focal epilepsy: from complexity to coherence to centrality.

Mirza N, Appleton R, Burn S, Carr D, Crooks D, du Plessis D, Duncan R, Farah JO, Josan V, Miyajima F, Mohanraj R, Shukralla A, Sills GJ, Marson AG, Pirmohamed M.

Hum Mol Genet. 2015 Aug 1;24(15):4306-16. doi: 10.1093/hmg/ddv163. Epub 2015 May 4.

PMID:
25941323
18.

Validation of a multigenic model to predict seizure control in newly treated epilepsy.

Shazadi K, Petrovski S, Roten A, Miller H, Huggins RM, Brodie MJ, Pirmohamed M, Johnson MR, Marson AG, O'Brien TJ, Sills GJ.

Epilepsy Res. 2014 Dec;108(10):1797-805. doi: 10.1016/j.eplepsyres.2014.08.022. Epub 2014 Sep 16.

PMID:
25282706
19.

What are the arguments for and against rational therapy for epilepsy?

Barker-Haliski M, Sills GJ, White HS.

Adv Exp Med Biol. 2014;813:295-308. doi: 10.1007/978-94-017-8914-1_24. Review.

PMID:
25012386
20.

A comprehensive neuropsychological description of cognition in drug-refractory juvenile myoclonic epilepsy.

Thomas RH, Walsh J, Church C, Sills GJ, Marson AG, Baker GA, Rees MI.

Epilepsy Behav. 2014 Jul;36:124-9. doi: 10.1016/j.yebeh.2014.04.027. Epub 2014 Jun 2.

PMID:
24938758
21.

Pharmacogenetics of antiepileptic drug-induced hypersensitivity.

Bloch KM, Sills GJ, Pirmohamed M, Alfirevic A.

Pharmacogenomics. 2014 Apr;15(6):857-68. doi: 10.2217/pgs.14.65. Review.

PMID:
24897291
22.

Advantages of repeated low dose against single high dose of kainate in C57BL/6J mouse model of status epilepticus: behavioral and electroencephalographic studies.

Tse K, Puttachary S, Beamer E, Sills GJ, Thippeswamy T.

PLoS One. 2014 May 6;9(5):e96622. doi: 10.1371/journal.pone.0096622. eCollection 2014.

23.

Sulthiame monotherapy for epilepsy.

Milburn-McNulty P, Powell G, Sills GJ, Marson AG.

Cochrane Database Syst Rev. 2014 Mar 9;(3):CD010062. doi: 10.1002/14651858.CD010062.pub2. Review.

PMID:
24609897
24.

Issues related to development of new antiseizure treatments.

Wilcox KS, Dixon-Salazar T, Sills GJ, Ben-Menachem E, White HS, Porter RJ, Dichter MA, Moshé SL, Noebels JL, Privitera MD, Rogawski MA.

Epilepsia. 2013 Aug;54 Suppl 4:24-34. doi: 10.1111/epi.12296. Review.

25.

Sulthiame add-on therapy for epilepsy.

Milburn-McNulty P, Powell G, Sills GJ, Marson AG.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD009472. doi: 10.1002/14651858.CD009472.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(10):CD009472.

PMID:
23543577
26.

Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy.

Brenner T, Sills GJ, Hart Y, Howell S, Waters P, Brodie MJ, Vincent A, Lang B.

Epilepsia. 2013 Jun;54(6):1028-35. doi: 10.1111/epi.12127. Epub 2013 Mar 6.

27.

N (w) -propyl-L-arginine (L-NPA) reduces status epilepticus and early epileptogenic events in a mouse model of epilepsy: behavioural, EEG and immunohistochemical analyses.

Beamer E, Otahal J, Sills GJ, Thippeswamy T.

Eur J Neurosci. 2012 Nov;36(9):3194-203. doi: 10.1111/j.1460-9568.2012.08234.x. Epub 2012 Sep 4.

PMID:
22943535
28.

Inflammation and epilepsy: the foundations for a new therapeutic approach in epilepsy?

Walker L, Sills GJ.

Epilepsy Curr. 2012 Jan;12(1):8-12. doi: 10.5698/1535-7511-12.1.8.

29.

Antiepileptic drug therapy: does mechanism of action matter?

Brodie MJ, Covanis A, Gil-Nagel A, Lerche H, Perucca E, Sills GJ, White HS.

Epilepsy Behav. 2011 Aug;21(4):331-41. doi: 10.1016/j.yebeh.2011.05.025. Epub 2011 Jul 16. Review.

PMID:
21763207
30.

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI, Chinthapalli K, Molokhia M, Johnson MR, O'Connor GD, Chaila E, Alhusaini S, Shianna KV, Radtke RA, Heinzen EL, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodiya SM, Goldstein DB, Deloukas P, Delanty N, Cavalleri GL, Pirmohamed M.

N Engl J Med. 2011 Mar 24;364(12):1134-43. doi: 10.1056/NEJMoa1013297.

31.

Combining antiepileptic drugs--rational polytherapy?

Brodie MJ, Sills GJ.

Seizure. 2011 Jun;20(5):369-75. doi: 10.1016/j.seizure.2011.01.004. Epub 2011 Feb 8. Review.

32.

SV2A in epilepsy: the plot thickens.

Sills GJ.

Epilepsy Curr. 2010 Mar;10(2):47-9. doi: 10.1111/j.1535-7511.2009.01351.x. No abstract available.

33.

Response to drug treatment in newly diagnosed epilepsy: a pilot study of (1)H NMR- and MS-based metabonomic analysis.

Al Zweiri M, Sills GJ, Leach JP, Brodie MJ, Robertson C, Watson DG, Parkinson JA.

Epilepsy Res. 2010 Feb;88(2-3):189-95. doi: 10.1016/j.eplepsyres.2009.11.005. Epub 2009 Dec 11.

PMID:
20005079
34.

Breaching the barrier and inflaming epilepsy research.

Sills GJ, Solomon T.

Epilepsy Curr. 2009 Sep-Oct;9(5):148-50. doi: 10.1111/j.1535-7511.2009.01324.x. No abstract available.

35.

Binasal visual field defects are not specific to vigabatrin.

Gonzalez P, Sills GJ, Parks S, Kelly K, Stephen LJ, Keating D, Dutton GN, Brodie MJ.

Epilepsy Behav. 2009 Nov;16(3):521-6. doi: 10.1016/j.yebeh.2009.09.003. Epub 2009 Oct 7.

PMID:
19815465
36.

Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing.

Makmor-Bakry M, Sills GJ, Hitiris N, Butler E, Wilson EA, Brodie MJ.

Clin Neuropharmacol. 2009 Jul-Aug;32(4):205-12. doi: 10.1097/WNF.0b013e318187972a.

PMID:
19620853
37.

High resolution micro-SPECT scanning in rats using 125I beta-CIT: effects of chronic treatment with carbamazepine.

Cain SM, Ruest T, Pimlott S, Patterson J, Duncan R, Dewar D, Sills GJ.

Epilepsia. 2009 Aug;50(8):1962-70. doi: 10.1111/j.1528-1167.2009.02095.x. Epub 2009 May 12.

38.

Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts.

Szoeke C, Sills GJ, Kwan P, Petrovski S, Newton M, Hitiris N, Baum L, Berkovic SF, Brodie MJ, Sheffield LJ, O'Brien TJ.

Epilepsia. 2009 Jul;50(7):1689-96. doi: 10.1111/j.1528-1167.2009.02059.x. Epub 2009 May 11.

39.

Novel therapeutic strategies for epilepsy--releasing the gene Genie.

Sills GJ.

Epilepsy Curr. 2009 Jan-Feb;9(1):26-7. doi: 10.1111/j.1535-7511.2008.01280.x. No abstract available.

40.

Comparison of different water-miscible solvents for the preparation of plasma and urine samples in metabolic profiling studies.

Alzweiri M, Watson DG, Robertson C, Sills GJ, Parkinson JA.

Talanta. 2008 Jan 15;74(4):1060-5. doi: 10.1016/j.talanta.2007.07.037. Epub 2007 Aug 14.

41.

Antiepileptic drug transport--of mice and men.

Sills GJ.

Epilepsy Curr. 2008 Mar-Apr;8(2):48-50. doi: 10.1111/j.1535-7511.2008.00234.x. No abstract available.

42.

Drug resistance in epilepsy: why is a simple explanation not enough?

Löscher W, Sills GJ.

Epilepsia. 2007 Dec;48(12):2370-2. No abstract available.

43.
44.

Predictors of pharmacoresistant epilepsy.

Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ.

Epilepsy Res. 2007 Jul;75(2-3):192-6.

PMID:
17628429
45.

Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy.

Stephen LJ, Sills GJ, Leach JP, Butler E, Parker P, Hitiris N, Leach VM, Wilson EA, Brodie MJ.

Epilepsy Res. 2007 Jul;75(2-3):122-9. Epub 2007 Jun 5.

PMID:
17553671
46.

Means, motive, and opportunity: establishing culpability in pharmacoresistant epilepsy.

Sills GJ.

Epilepsy Curr. 2007 Mar-Apr;7(2):51-3. No abstract available.

47.

Sudden unexpected death in epilepsy: a search for risk factors.

Hitiris N, Suratman S, Kelly K, Stephen LJ, Sills GJ, Brodie MJ.

Epilepsy Behav. 2007 Feb;10(1):138-41. Epub 2006 Dec 29.

PMID:
17196884
48.
49.

Excitable but lacking in energy: contradictions in the human epileptic hippocampus.

Sills GJ.

Epilepsy Curr. 2006 Jan-Feb;6(1):6-7. No abstract available.

50.

The mechanisms of action of gabapentin and pregabalin.

Sills GJ.

Curr Opin Pharmacol. 2006 Feb;6(1):108-13. Epub 2005 Dec 22. Review.

PMID:
16376147

Supplemental Content

Loading ...
Support Center